<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Here, we aimed to investigate the role of connective tissue growth factor (CTGF) in <z:e sem="disease" ids="C1332128" disease_type="Neoplastic Process" abbrv="">peritoneal carcinomatosis</z:e> (PC) associated with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and to characterize the underlying mechanism of CTGF mediating <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>EXPERIMENTAL DESIGN: A cohort of 136 CRC patient specimens was analyzed in this study </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines were used for in vitro <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> assay and in vivo peritoneal dissemination experiment </plain></SENT>
<SENT sid="3" pm="."><plain>Recombinant CTGF protein treatment, transfection of CTGF expression plasmids, and knockdown of CTGF expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells were utilized to evaluate the integrin α5, which served as a target of CTGF in inhibiting peritoneal seeding </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The analysis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues revealed an inverse correlation between CTGF expression and prevalence of PC </plain></SENT>
<SENT sid="5" pm="."><plain>Lower CTGF level in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients was associated with higher peritoneal recurrence rate after surgery </plain></SENT>
<SENT sid="6" pm="."><plain>Inducing CTGF expression in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells resulted in decreased incidence of PC and increased rate of mice survival </plain></SENT>
<SENT sid="7" pm="."><plain>The mice received intraperitoneal injection of recombinant CTGF protein simultaneously with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells or following <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation; in both cases, peritoneal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> dissemination was found to be effectively inhibited in the mouse model </plain></SENT>
<SENT sid="8" pm="."><plain>Functional assay revealed that CTGF significantly decreased the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> ability, and integrin α5 was confirmed by reverse transcriptase PCR and functional blocking assay as a downstream effector in the CTGF-mediated inhibition of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: CTGF acts as a molecular predictor of PC and could be a potential therapeutic target for the chemoprevention and treatment of PC in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
</text></document>